David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2976
BancFirst
BANF
$3.76B
| $476K | ﹤0.01% |
9,118
+4,633
| +103% | +$251K |
|
|
CMD
2977
PUT
DELISTED
Cantel Medical Corporation
CMD
| $475K | ﹤0.01% |
+7,100
| New | +$538K |
|
2978
Omnicom Group
OMC
$24B
| $474K | ﹤0.01% |
+6,488
| New | +$487K |
|
2979
Church & Dwight Co
CHD
$24.4B
| $471K | ﹤0.01% |
6,606
-8,459
| -56% | -$557K |
|
2980
Invesco QQQ Trust
QQQ
$485B
| $471K | ﹤0.01% |
+2,624
| New | +$445K |
|
|
RVNC
2981
DELISTED
Revance Therapeutics, Inc.
RVNC
| $469K | ﹤0.01% |
29,729
-70,761
| -70% | -$1.23M |
|
2982
Globe Life
GL
$13.3B
| $468K | ﹤0.01% |
5,714
-596
| -9% | -$48.7K |
|
2983
Nelnet
NNI
$4.59B
| $468K | ﹤0.01% |
8,503
-174
| -2% | -$9.35K |
|
|
CMD
2984
DELISTED
Cantel Medical Corporation
CMD
| $468K | ﹤0.01% |
7,001
-41,586
| -86% | -$3.15M |
|
|
SFE
2985
DELISTED
Safeguard Scientifics, Inc.
SFE
| $465K | ﹤0.01% |
42,899
+1,250
| +3% | +$12.7K |
|
|
GES
2986
DELISTED
Guess Inc
GES
| $463K | ﹤0.01% |
23,617
-240,750
| -91% | -$5.1M |
|
|
WW
2987
PUT
DELISTED
WW International
WW
| $463K | ﹤0.01% |
23,000
-16,500
| -42% | -$456K |
|
2988
CALL
LyondellBasell Industries
LYB
$20B
| $462K | ﹤0.01% |
+5,500
| New | +$475K |
|
2989
PUT
LCI Industries
LCII
$2.52B
| $461K | ﹤0.01% |
6,000
-4,700
| -44% | -$372K |
|
|
SF
2990
Stifel
SF
$12B
| $461K | ﹤0.01% |
19,676
-13,341
| -40% | -$302K |
|
|
TECD
2991
CALL
DELISTED
Tech Data Corp
TECD
| $461K | ﹤0.01% |
4,500
-5,600
| -55% | -$547K |
|
2992
PUT
Gen Digital
GEN
$17.6B
| $460K | ﹤0.01% |
20,000
-80,000
| -80% | -$1.74M |
|
|
PTLA
2993
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $459K | ﹤0.01% |
+13,235
| New | +$382K |
|
2994
AAR Corp
AIR
$5.53B
| $458K | ﹤0.01% |
14,092
-2,990
| -18% | -$108K |
|
2995
Adient
ADNT
$1.43B
| $456K | ﹤0.01% |
35,161
-9,085
| -21% | -$159K |
|
|
HMTV
2996
DELISTED
Hemisphere Media Group, Inc.
HMTV
| $455K | ﹤0.01% |
32,267
-3,385
| -9% | -$45.2K |
|
|
DLPH
2997
CALL
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
| $449K | ﹤0.01% |
23,300
-34,600
| -60% | -$640K |
|
|
SECO
2998
DELISTED
Secoo Holding Limited ADR
SECO
| $448K | ﹤0.01% |
+5,112
| New | +$455K |
|
|
BLD
2999
CALL
DELISTED
TopBuild
BLD
| $447K | ﹤0.01% |
6,900
-59,900
| -90% | -$3.37M |
|
3000
CALL
AeroVironment
AVAV
$7.52B
| $445K | ﹤0.01% |
6,500
-63,600
| -91% | -$4.8M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.